| Cholesterol biosynthesis |
16 |
0.0 |
DHCR7, IDI1, FDPS, DHCR24 |
| Fatty acid biosynthesis |
10 |
0.0 |
PRKAB2,PTGS1, SCD, FASN |
| Negative regulation of transcription factor activity |
5 |
7.9E-5 |
ID1, ID3, ID2 |
| Negative regulation of cell proliferation |
12 |
8.5E-5 |
IL6, MDM2, GPNMB, IL8, EREG |
| Regulation of transcription, DNA-dependent |
62 |
1.17E-4 |
BHLHB2, MEOX2, MEOX2, ZNF655 |
| Anti-apoptosis |
8 |
6.23E-4 |
DDAH2, MALT1, HIPK3, IER3, BNIP2 |
| Complement activation, classical pathway |
5 |
9.76E-4 |
C1S, SERPING1, C7, CD46 |
| Keratinocyte differentiation |
4 |
0.002 |
PTGS1, EREG, PTGS2 |
| Cell-cell signaling |
19 |
0.002 |
NDP, NAMPT, IL6, LEP, AREG |
| Negative regulation of cell adhesion |
3 |
0.002 |
CD164, Q8NFD8_HUMAN, ADAMDEC |
| Regulation of cyclin-dependent protein kinase activity |
4 |
0.003 |
CCNA2, CCNE2, CDKN2A, RGC32 |
| Cell division |
4 |
0.004 |
CAPG, CDC2, CCNB1, CCND2, CCNA2 |
| Cytokinesis |
4 |
0.005 |
DIAPH2, ANLN, PRC1 |
| Mitosis |
11 |
0.006 |
PBK, CAPG, CDC2, CCNB1, CCNA2 |
| Chemotaxis |
7 |
0.008 |
CXCL5, CXCL2, IL8, CXCL6, CXCL1 |
| Positive regulation of mitosis |
3 |
0.008 |
EREG, NUSAP1 |
| Positive regulation of I-kB kinase/NF-kB cascade |
6 |
0.009 |
MALT1, CASP1, TNFSF10, TRADD |
| Regulation of progression through cell cycle |
15 |
0.012 |
CDC2, CCNB1, MDM2, CCND2, FOSB |
| TGF-beta receptor signaling pathway |
3 |
0.012 |
SMAD7, LTBP2, SMAD3 |
| Positive regulation of cell proliferation |
8 |
0.012 |
NAMPT, IL6, CXCL5, TSHR, TTK |
| Angiogenesis |
5 |
0.015 |
IL8, EREG, ANG, ANGL4_HUMAN |
| Innate immune response |
5 |
0.02 |
C1S, SERPING1, C7, CD46 |
| Negative regulation of lipoprotein lipase activity |
2 |
0.021 |
ANGL4_HUMAN |
| Cytokinesis after mitosis |
2 |
0.021 |
NUSAP1 |
| Cell cycle checkpoint |
3 |
0.024 |
RAD1, CCNE2, CDKN2A |
| Cell cycle arrest |
4 |
0.024 |
DHCR24, IL8, CDKN2A, Q8N9B5
|
| Protein ubiquitination |
3 |
0.032 |
MYLIP, MDM2, FBXO9 |
| Negative regulation of transcription |
3 |
0.032 |
NAB1, EREG, ID1, ID4, ID3 |
